Mark Diamond

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Mark Diamond
Mark Diamond
Chief Executive, Managing Director / Antisense Therapeutics
Most Notable Role

Mark Diamond has over 30 years of experience in the pharmaceutical and biotechnology industry.

Before joining Antisense Therapeutics Limited as managing director and chief executive in October 2001, Mr Diamond was with Faulding Pharmaceuticals as senior manager of business development and In-licensing for its European operation based in the UK, international business development manager in Australia, and director of project planning and business development in the US.

Lists and Charts

Revenue

Rank Company #
969th - Antisense Therapeutics $1.58m
1332 public companies - non WA ranked by total revenue
View Full List

Roles

2023
Non-Executive Director
Dimerix
2001
Chief Executive, Managing Director
Antisense Therapeutics
Year started and most recent title

Share Transactions

21/10/24
$110.15k Issued
Dimerix
28/04/22
Bought
Antisense Therapeutics
22/12/21
$112.93k Issued
Antisense Therapeutics
Total value as at the date of the transaction
Powered by Morningstar ®

Person Activity

Mark Diamond
NEW ROLE: Non-Executive Director, Dimerix 25 Jul 2024
Mark Diamond
NEW ROLE: Chief Executive, Managing Director, Antisense Therapeutics 03 Nov 2020

Related Information

Access to our data for Mark Diamond is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Mark Diamond is linked to 3 organisations which are included in 1 list - Public Companies - non WA.

To see the data you will need to Subscribe.

X